Figure 1

The three Kaplan Meier curves show differences in cumulative survival between with low-risk, low-intermediate, high-intermediate and high-risk categories using a baseline IPI model (A) and two revised IPI models. The first (rIPI1) incorporates flow cytometry and immunohistochemistry as routine staging (B) and the second IPI model (rIPI2) additionally incorporates molecular testing using IgH/IgL analysis (C).